Hola,
Are you new here?

MYCure

financed

Innovative cancer therapy through Myc inhibition taking OMO 103 to market

Cancer is a global challenge with 9 millions (M) deaths annually and new cases projected to rise by 70% in the 20 years, and there is a clear and pressing need for more effective therapies. In the EU, lung cancer is the most commo... see more

31/12/2022

PEPTOMYC

6M€

Project Budget: 6M€

Project leader

PEPTOMYC La realizacion y desarrollo de estudios y proyectos de investigacion cientifica y tecnica en el ambito de las enfermedades oncologicas y tum...

TRL 4-5 | 6M€

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 2 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2022-12-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada does 5 years

0% 36% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

PEPTOMYC

2.22M€ | Leader

INGETEAM POWER TECHNOLOGY

1.30M€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 40 months Date Start: 2019-08-28
End date: 2022-12-31

Project leader

PEPTOMYC La realizacion y desarrollo de estudios y proyectos de investigacion cientifica y tecnica en el ambito de las enfermedades oncologicas y tum...

TRL 4-5 | 6M€

Project Budget 6M€

participation deadline Sin fecha límite de participación.

Project description Cancer is a global challenge with 9 millions (M) deaths annually and new cases projected to rise by 70% in the 20 years, and there is a clear and pressing need for more effective therapies. In the EU, lung cancer is the most common cancer in men and the third most common in women, with 2 M new cases in 2018 accounting for ~20% of all cancer deaths. Despite considerable recent advances in lung cancer treatment, current treatments are still too often ineffective or highly toxic. Peptomyc is a unique biotech SME that is revolutionizing cancer treatment with its ground-breaking innovative cancer therapies inhibiting Myc. Our patented product OMO-103 is able to penetrate the nuclei, attack Myc and kill cancer cells. In contrast, most current therapies attack redundant cell surface receptors or proteins that can be compensated by tumours, which then evolve resistance. Our company combines scientific excellence with sound business acumen: our scientific leadership in Myc inhibition builds on 20 years of world-class scientific record, and in just 3 years after the foundation, we closed 2 rounds of equity investments with Venture Capitals. Peptomyc aims at licensing its technology to pharmaceutical companies. Financing through this SME Instrument project will enable us to take to the market our first product, OMO-103 by completing clinical trials and reach a licensing agreement with a pharmaceutical company for full scale production and commercialization. Our results so far show that OMO-103 is: Safer (no toxicity), More efficient (no resistance observed), and More effective (increased survival in lung cancer models). With MYCure, we will take to market our first-in-class Myc inhibitor OMO-103 to treat non-small cell lung cancer, for which the global market is expected to reach 14 bn € by 2023, a total addressable market of which OMO-103 is poised to gain considerable share of up to 15% by 2029 thanks to a sound business plan developed under the SME Instrument.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers